Kymera Therapeutics

Today, tune into a fireside chat with our CEO, Nello Mainolfi, at the Goldman Sachs Annual Global #Healthcare Conference where he’ll discuss the latest developments across our pipeline and what’s ahead for Kymera. Check out the live webcast here: https://bit.ly/3VbpIDb #TPD #Biotech 

#HidradenitisSuppurativa is a chronic, painful skin disease whereby there remains a tremendous need for new treatment options for patients, and for #HSAwarenessWeek we hope to increase awareness and understanding for this debilitating disease. We’re driven to revolutionize the treatment of immuno-inflammatory diseases by building an industry leading pipeline of oral medicines - learn more about #KT474, currently in Phase 2 trials for HS and AD: https://bit.ly/3KCXz2Z #RevolutionizingImmunology

In honor of #PrideMonth, we were delighted to host SpeakOUT for a panel to discuss LGBTQIA+ voices and allyship in the workplace. We are committed to fostering a culture where we recognize our differences, inviting curiosity and inclusivity, so that everyone is valued, seen, and heard, and we look forward to continuing to celebrate, learn, and grow as allies of the LGBTQIA+ community. #Belong

Today at the 15th Annual T-Cell Lymphoma Forum, Dr. Tatyana Feldman will present on KT-333, our potent, highly selective degrader of STAT3. She'll recap data highlighting the potential of degraders for targeting this previously undruggable transcription factor. Learn more about this novel program on our website: https://bit.ly/3KCXz2Z #TPD #ReinventingMedicine 

This morning, join Nello Mainolfi, our CEO, and Jared Gollob, our CMO, for a fireside chat at the Jefferies Global #Healthcare Conference where they’ll discuss our recent progress and upcoming milestones. You can watch the live webcast at: https://bit.ly/3yJtBHX #JefferiesHealthcare #TPD

This week, Kymerians Eric Kuhn and Dirk Walther are presenting posters at the American Society For Mass Spectrometry (ASMS) Annual Conference! Advanced #proteomics technologies provide deep insights at high resolution and dimensionality, and these innovative strategies help power our robust #drugdiscovery engine. #ASMS2024 #TPD #Pioneer

To complete our #MonthofService, we worked with the Urban Farming Institute of Boston (UFI) to prepare fields to grow fresh, affordable, and nutritious food for residents of our local community. Learn more about this important initiative and how to get involved here: https://lnkd.in/eQg5KEXb   #KymeraCares  

Today we shared new clinical data being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from our ongoing KT-253 Phase 1 oncology trial. KT-253 is a highly potent and selective degrader that targets MDM2, and the findings shared today continue to support our therapeutic hypothesis for MDM2 degradation and the potential to improve the therapeutic index compared to small molecule inhibitors for a variety of cancers. Read the full press release and view the poster here: https://bit.ly/3Ra3X5F #ASCO24 #TPD #ReinventingMedicine

Today our CFO, Bruce Jacobs, will speak on a panel at the ABFO National Conference! He'll discuss how we foster a #culture that empowers and inspires Kymerians, enabling our team to learn and grow while working to improve the lives of patients. #Biotech #Pioneer #Collaborate #Belong 

To recognize National Asthma and Allergy Awareness Month, we were thrilled to host Dr. Geoff Chupp where he discussed his decades of innovative research that focuses on the care of patients with severe asthma and other complicated airway diseases and provided important perspectives on patient care. Thank you, Dr. Chupp, for taking the time to meet with our team! #RevolutionizingImmunology